DTIC and combination therapy for melanoma. II. Escalating schedules of DTIC with BCNU, CCNU, and vincristine.

Suppr

超能文献

作者信息

Hill G J, Metter G E, Krementz E T, Fletcher W S, Golomb F M, Ramirez G, Grage T B, Moss S E

出版信息

Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1989-92.

PMID:393384

Abstract

摘要

相似文献

DTIC and combination therapy for melanoma. II. Escalating schedules of DTIC with BCNU, CCNU, and vincristine.

Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1989-92.

DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065).

Cancer Treat Rep. 1976 May;60(5):601-9.

cis-Dichlorodiammineplatinum(II) and DTIC in malignant melanoma.

Cancer Treat Rep. 1979 Nov-Dec;63(11-12):2009-10.

DTIC (NSC-45388) studies in the southwest oncology group.

Cancer Treat Rep. 1976 Feb;60(2):189-92.

DTIC (NSC-45388) in malignant melanoma: a perspective.

Cancer Treat Rep. 1976 Feb;60(2):165-76.

Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.

J Exp Clin Cancer Res. 2000 Mar;19(1):21-34.

Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group.

Cancer Treat Rep. 1976 Feb;60(2):183-7.

A clinical trial of procarbazine plus vincristine plus bis-chloroethyl-nitrosourea plus imidazole carboxamide dimethyl triazeno in metastatic malignant melanoma.

Med Pediatr Oncol. 1975;1(2):107-11. doi: 10.1002/mpo.2950010205.

Procarbazine, vincristine, CCNU, and cyclophosphamide (POCC) in the treatment of metastatic malignant melanoma.

Cancer Treat Rep. 1980 Jan;64(1):139-42.

Influence of therapy on the antioxidant status in patients with melanoma.

J Clin Pharm Ther. 2008 Apr;33(2):179-85. doi: 10.1111/j.1365-2710.2008.00909.x.

引用本文的文献

Systemic therapy of non-resectable metastatic melanoma.

Cancers (Basel). 2010 May 26;2(2):955-69. doi: 10.3390/cancers2020955.

Current research and development of chemotherapeutic agents for melanoma.

Cancers (Basel). 2010 Apr 9;2(2):397-419. doi: 10.3390/cancers2020397.

Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma.

Oncologist. 2012;17(11):1376-85. doi: 10.1634/theoncologist.2011-0427. Epub 2012 Sep 28.

Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomas.

World J Clin Oncol. 2012 Mar 10;3(3):32-42. doi: 10.5306/wjco.v3.i3.32.

Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma.

Dermatol Res Pract. 2012;2012:259170. doi: 10.1155/2012/259170. Epub 2011 Dec 15.

Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma.

Med Oncol. 1995 Mar;12(1):35-40. doi: 10.1007/BF01571406.

Synthesis of cysteinylphenol, cysteaminylphenol, and related compounds, and in vivo evaluation of antimelanoma effect.

Arch Dermatol Res. 1987;279(4):219-25. doi: 10.1007/BF00417318.

Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study Group.

Cancer Chemother Pharmacol. 1990;27(2):81-4. doi: 10.1007/BF00689087.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验